MK-7110

Home
Ligands
MK-7110

GtoPdb Ligand ID: 11395

Synonyms: CD24-Fc [2] | CD24Fc

Compound class: Peptide or derivative

Comment: MK-7110 (originally OncoImmune's CD24Fc) is a synthetic protein that fuses the nonpolymorphic regions of CD24 (which is an agonist of Siglec-10) to the Fc region of human IgG1 [2]. It.is being investigated as a modulator of the innate immune system, originally as an intervention to ameliorate graft-versus-host disease in leukemia patients receiving stem cell transplants, or autoimmune diseases. The peptide's sequence was extracted from OncoImmune's patent US20130231464A1 [4]; the first 30 amino acids are the CD24 region and the remainder belong to the IgG1 Fc domain.

SARS-CoV-2 and COVID-19: Preclinical evidence in primate viral infection models showed that MK-7110 offered potential as a non-antiviral biological modality that could be applied to reduce inflammation in SARS-CoV-2 infection.

References
1. Altevogt P, Sammar M, Hüser L, Kristiansen G. (2021) Novel insights into the function of CD24: A driving force in cancer. Int J Cancer, 148 (3): 546-559. [PMID:32790899]
2. Chen GY, Tang J, Zheng P, Liu Y. (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science, 323 (5922): 1722-5. [PMID:19264983]
3. Toubai T, Rossi C, Oravecz-Wilson K, Zajac C, Liu C, Braun T, Fujiwara H, Wu J, Sun Y, Brabbs S et al.. (2017) Siglec-G represses DAMP-mediated effects on T cells. JCI Insight, 2 (14). [PMID:28724800]
4. Zheng X, Wu W, Liu Y, Zheng P. (2013) Methods of use of soluble cd24 for therapy of rheumatoid arthritis. Patent number: US20130231464A1. Assignee: Oncolmmune, Inc.. Priority date: 28/04/2010. Publication date: 05/09/2013.

References

1. Altevogt P, Sammar M, Hüser L, Kristiansen G. (2021)
Novel insights into the function of CD24: A driving force in cancer.
Int J Cancer, 148 (3): 546-559. [PMID:32790899]

2. Chen GY, Tang J, Zheng P, Liu Y. (2009)
CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.
Science, 323 (5922): 1722-5. [PMID:19264983]

3. Toubai T, Rossi C, Oravecz-Wilson K, Zajac C, Liu C, Braun T, Fujiwara H, Wu J, Sun Y, Brabbs S et al.. (2017)
Siglec-G represses DAMP-mediated effects on T cells.
JCI Insight, 2 (14). [PMID:28724800]

4. Zheng X, Wu W, Liu Y, Zheng P. (2013)
Methods of use of soluble cd24 for therapy of rheumatoid arthritis.
Patent number: US20130231464A1. Assignee: Oncolmmune, Inc.. Priority date: 28/04/2010. Publication date: 05/09/2013.